Johnson & Johnson accelerates drug development with artificial intelligence
O.D.English Section / 29 aprilie
American pharmaceutical giant Johnson & Johnson is increasingly relying on artificial intelligence to significantly reduce the time required to research and develop new treatments, at a time when the pharmaceutical industry is looking for solutions to shorten extremely expensive and time-consuming processes. According to the company's IT director, Jim Swanson, quoted by Reuters, AI has already managed to halve the time required to identify promising leads for the development of new drugs.
















































































